Vimarsana
Biggest News Aggregation in the World

Analysis Group Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Analysis Group Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Analysis Group Inc Today - Breaking & Trending Today

Apple's 27% App Store Fee Plan Gets Skeptical Reception by Judge - Vimarsana News

Apple's 27% App Store Fee Plan Gets Skeptical Reception by Judge

(Bloomberg) -- Apple Inc.’s attempts to justify the 27% fee it charges developers for purchases outside its App Store backfired as a skeptical federal judge questioned an executive about a company-commissioned study showing half that rate would be reasonable.Most Read from BloombergChina Attempts to End Property Crisis With Broad Rescue PackageA 25-Year-Old BofA Trader Dies Suddenly at Industry OutingWith a BlackRock CEO, $9 Trillion Vanguard Braces for TurbulenceVoters Prefer Trump Over Biden o

Source: yahoo.com
Real-World Users of Triple Therapy for Asthma in the US - Vimarsana News

Real-World Users of Triple Therapy for Asthma in the US

This retrospective cohort study evaluated baseline demographics, clinical characteristics, and treatment patterns of US patients with asthma who newly initiated single- or multiple-inhaler triple therapy.

Source: ajmc.com
Real World Evidence Solutions Market Set for Rapid Growth - Vimarsana News

Real World Evidence Solutions Market Set for Rapid Growth

Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The

COVID-19 pandemic study shows adherence to in - Vimarsana News

COVID-19 pandemic study shows adherence to in

<p>A new <a href="https://doi.org/10.1016/j.ajic.2023.10.010">study</a> published today in the <em>American Journal of Infection Control</em> (AJIC), based on a survey of healthcare professionals conducted during the height of the COVID-19 pandemic, suggests that new efforts may be needed to strengthen infection prevention precautions and protect staff members at the highest risk of exposure to dangerous pathogens. This is believed to be the first study of pandemic-era infection precautions to include a broad variety of healthcare jobs. Researchers found...

Study Compares Work Productivity Loss, Cost Savings in Esketamine Nasal Spray vs Quetiapine Extended-Release for TRD - Vimarsana News

Study Compares Work Productivity Loss, Cost Savings in Esketamine Nasal Spray vs Quetiapine Extended-Release for TRD

“Among employed adults with TRD, esketamine nasal spray treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine extended-release treatment.”